Form 4: ImmunityBio Director Sells Shares
Insider Transaction (Form 4)
Cheryl Cohen, a Director of ImmunityBio, Inc., sold 81,056 shares of common stock on October 2, 2026 for $10.50 per share.
Summary
- Option exercise/conversion: acquired 55,979 Common Stock at $2.98 ($166,817) on October 2, 2026; holds 181,365 after (Direct).
- Open-market sale: disposed of 81,056 Common Stock at $10.50 ($851,088) on October 2, 2026; holds 100,309 after (Direct).
- Option exercise/conversion: disposed of 55,979 Stock Option (right to buy) on October 2, 2026; holds 55,979 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $851,088 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Cheryl Cohen — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-02 | Option exercise/conversion | Common Stock | 55,979 | $3 | $166.8K | 181,365 |
| 2026-10-02 | Open-market sale | Common Stock | 81,056 | $11 | $851.1K | 100,309 |
| 2026-10-02 | Option exercise/conversion | Stock Option (right to buy) | 55,979 | — | — | 55,979 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-02 | Option exercise/conversion (55,979 shares) |
| 2026-10-02 | Open-market sale (81,056 shares) |
| 2026-10-02 | Option exercise/conversion (55,979 shares) |
Keywords
insider transaction, Form 4, IBRX, ImmunityBio, Inc., bearish, Cheryl Cohen
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.